A phase I dose escalation study of a 2 day oral lapatinib chemosensitization pulse given prior to weekly intravenous Abraxane (Tm) [paclitaxel] in patients with advanced solid tumors.

Trial Profile

A phase I dose escalation study of a 2 day oral lapatinib chemosensitization pulse given prior to weekly intravenous Abraxane (Tm) [paclitaxel] in patients with advanced solid tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jul 2014

At a glance

  • Drugs Lapatinib (Primary) ; Paclitaxel
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Oct 2012 Planned End Date changed from 1 Feb 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 10 Oct 2012 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
    • 23 Apr 2008 The expected completion date for this trial is now 1 Feb 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top